Tactduo
(E,3R,5S)-7-[4-(4-Fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 446157.
Registration
- Applicants
- 1
- Registrations
- 4
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Sandoz South Africa (Pty) Ltd | Tactduo | 10/5, 10/10, 10/20, 10/40 | 561081, 561082, 561083, 561084 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Tactduo 10/5 EACH TABLET CONTAINS EZETIMIBE 10,0 mg ROSUVASTATIN CALCIUM EQUIVALENT TO ROSUVASTATIN 5,0 mg | 10/5 | 56108156/7.5/1081 | Registered | Not determined | None |
| Tactduo 10/10 EACH TABLET CONTAINS EZETIMIBE 10,0 mg ROSUVASTATIN CALCIUM EQUIVALENT TO ROSUVASTATIN 10,0 mg | 10/10 | 56108256/7.5/1082 | Registered | Not determined | None |
| Tactduo 10/20 EACH TABLET CONTAINS EZETIMIBE 10,0 mg ROSUVASTATIN CALCIUM EQUIVALENT TO ROSUVASTATIN 20,0 mg | 10/20 | 56108356/7.5/1083 | Registered | Not determined | None |
| Tactduo 10/40 EACH TABLET CONTAINS EZETIMIBE 10,0 mg ROSUVASTATIN CALCIUM EQUIVALENT TO ROSUVASTATIN 40,0 mg | 10/40 | 56108456/7.5/1084 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Ezetimibe
Consolidated Schedules 06 July 2026, line 6302
S4: Rosuvastatin
Consolidated Schedules 06 July 2026, line 7853
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.